Article

TTT trial to test potential treatment for wet AMD

Mountain View, CA-IRIDEX Corp. has completed enrollment in a clinical trial for its TTT4CNV, to determine whether trans-pupillary thermotherapy (TTT) laser treatment can reduce the risk of vision loss for patients with occult wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia
June 4th 2025

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Study highlights retinal vulnerability in patients with bipolar and depressive disorders
June 4th 2025

Study highlights retinal vulnerability in patients with bipolar and depressive disorders

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

FDA accepts NDA for Tenpoint Therapeutics' brimochol PF for presbyopia
June 3rd 2025

FDA accepts NDA for Tenpoint Therapeutics' brimochol PF for presbyopia

The Vision Council weighs in on IEEPA tariff ruling and appeal
June 3rd 2025

The Vision Council weighs in on IEEPA tariff ruling and appeal

© 2025 MJH Life Sciences

All rights reserved.